Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

SPR206

Other · developed by Spero Therapeutics

Phase 1 Most advanced trial (none active)
SPRO Developer
1 Registered trials

What is SPR206?

SPR206 is an investigational drug studied in Renal Impairment.

At a glance

Drug type
Other
Therapy area
Renal & urology
Developer
Spero Therapeutics (SPRO)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1
UNII
HL5KS3G9R2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04865393 Phase 1 Renal Impairment Completed SPRO

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Renal Impairment

More from Spero Therapeutics

SPR720 Phase 2 SPR741 Phase 1

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the SPRO page.

Follow SPRO, the company behind SPR206

See SPRO's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

SPRO catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.